166 related articles for article (PubMed ID: 8656271)
41. Melanoma: adjuvant therapy and other treatment options.
Terando A; Sabel MS; Sondak VK
Curr Treat Options Oncol; 2003 Jun; 4(3):187-99. PubMed ID: 12718796
[TBL] [Abstract][Full Text] [Related]
42. [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
Hauschild A; Dummer R; Garbe C; Kaufmann R; Schadendorf D; Soyer HP; Stadler R; Tilgen W
Hautarzt; 1998 Mar; 49(3):167-9. PubMed ID: 9565782
[No Abstract] [Full Text] [Related]
43. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
Messori A; Becagli P; Trippoli S; Tendi E
Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant therapies for malignant melanoma.
Olofsson Bagge R; Ny L
Br J Surg; 2016 Aug; 103(9):1095-6. PubMed ID: 27246114
[No Abstract] [Full Text] [Related]
45. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant interferon for melanoma.
Wheatley K; Ives N
Ann Oncol; 2002 Aug; 13(8):1319-20; author reply 1320. PubMed ID: 12181258
[No Abstract] [Full Text] [Related]
47. [After removal of a malignant melanoma. Enhancing the immune system!].
MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
[No Abstract] [Full Text] [Related]
48. [Drug clinics. How I treat cutaneous melanoma].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 1998 Jan; 53(1):4-6. PubMed ID: 9555173
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant application of interferons.
el Kassas H; Kirkwood JM
Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
[No Abstract] [Full Text] [Related]
50. Does adjuvant vaccine therapy really have activity in malignant melanoma?
Wheatley K; Ives NJ; Lorigan P
J Clin Oncol; 2007 Oct; 25(29):4693; author reply 4693-5. PubMed ID: 17925569
[No Abstract] [Full Text] [Related]
51. A case series of paediatric and adolescent melanoma.
Stefanaki C; Soura E; Plaka M; Chasapi V; Polydorou D; Antoniou C; Stratigos A
Eur J Dermatol; 2018 Feb; 28(1):120-122. PubMed ID: 29180317
[No Abstract] [Full Text] [Related]
52. The promise of new technologies and therapies.
Reintgen DS
Cancer Control; 2002; 9(1):4-5. PubMed ID: 11907460
[No Abstract] [Full Text] [Related]
53. Adjuvant interferon in the treatment of melanoma.
Kirkwood JM
Br J Cancer; 2000 May; 82(10):1755-6. PubMed ID: 10817514
[No Abstract] [Full Text] [Related]
54. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
55. Management of cutaneous melanoma.
Tsao H; Atkins MB; Sober AJ
N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
[No Abstract] [Full Text] [Related]
56. Adjuvant interferon: extended follow-up times needed?
Thoren FB; Strannegård Ö
Lancet Oncol; 2011 May; 12(5):419. PubMed ID: 21536217
[No Abstract] [Full Text] [Related]
57. Recurrent laryngeal metastasis of a malignant melanoma: surgical therapy with the first application of mitomycin C.
Echternach M; Arndt S; Mattern D; Maier W; Richter B
J Otolaryngol Head Neck Surg; 2009 Feb; 38(1):E19-22. PubMed ID: 19344599
[No Abstract] [Full Text] [Related]
58. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
Kimyai-Asadi A; Usman A
J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
[TBL] [Abstract][Full Text] [Related]
59. Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
[TBL] [Abstract][Full Text] [Related]
60. [Guidelines for stage I to III melanoma].
Guillot B; Dalac S; Denis M; Dupuy A; Emile JF; De La Fouchardiere A; Hindie E; Jouary T; Lassau N; Mirabel X; Piperno Neumann S; De Raucourt S; Vanwijck R
Bull Cancer; 2016 Sep; 103(9):743-52. PubMed ID: 27456259
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
